Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Los Angeles › NPI 1619621497
Lab

BZD Labs

BZD Labs was paid $1.37M by Medicaid between Dec 2021 and Jun 2023, across 8 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 57% of everything it billed.

33Billing provider infoBZD LABS
LOS ANGELES, CA 90004
33aNPI1619621497assigned 02/09/2022
28Total paid$1.37M
24GClaims38,549
24DCodes billed8
24AFirst – last monthDec 2021 – Jun 2023
Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#172 of 561
Median peer was paid$222K
This provider vs. median6.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$250K$500K$750K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2021324$7K
202216,451$624K
202321,774$740K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 57% 14,476 3,692 $776K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 28% 13,095 3,061 $389K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 8.6% 6,579 1,954 $118K
K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count 5.6% 3,145 3,062 $77K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 892 570 $8K
G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source <1% 106 103 $2K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 68 51 $537.49
99001 <1% 188 180 $30.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDOBRIN, BORIS (CEO)